Associated Genetic Biomarkers
Signal transducer and activator of transcription 5A (STAT5A) is a gene that encodes a protein that functions as a transcription activator. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
STAT5A is altered in 0.66% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, prostate adenocarcinoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in STAT5A are STAT5A Mutation (0.26%), STAT5A Amplification (0.06%), STAT5A Loss (0.05%), STAT5A Q368Rfs*2 (0.01%), and STAT5A R649W (0.01%) .
STAT5A status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT5A status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT5A status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT5A Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT5A as an inclusion criteria .
Significance of STAT5A in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.